Abstract
Introduction of CKD-MBD changed clinical attitudes for the therapy of metabolic bone disease in maintenance dialysis therapy as the systemic diseases of calcium phosphate metabolism. We present the variation of target serum calcium, phosphate and parathyroid hormone levels in the guidelines of US and European countries. We also review the management of drug use especially concomitant active vitamin D metabolites and calcium carbonate to cinacalcet prescription.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
